Recent studies revealed that multiple factors including MGMT mutation, tumor immune microenvironment, inflammasome and PI3K/Akt pathways could contribute to individualized TMZ efficacy [25–27], whereas there still lack of strategies to increase the chemotherapy sensitivity. The gene discussed is MGMT; the disease is neoplasm.